Myeloma Today: Spring 2026
From newly approved 4-drug frontline regimens to the expanding role of CAR T-cell therapy and bispecific antibodies, this Spring 2026 edition of Myeloma Today breaks down the clinical advances redefining what’s possible for myeloma patients today. You’ll also discover how a global movement reached over 60 million people during Myeloma Action Month — and why that momentum matters.